JWH-098
JWH-098 is a synthetic cannabinoid receptor agonist from the naphthoylindole family. It is the indole 2-methyl derivative of a closely related compound JWH-081, but has markedly different affinity for the CB1 and CB2 receptors. While JWH-081 is around 10x selective for CB1 over CB2, in JWH-098 this is reversed, and it is around 4 times weaker than JWH-081 at CB1 while being six times more potent at CB2, giving it a slight selectivity for CB2 overall. This makes JWH-098 a good example of how methylation of the indole 2-position in the naphthoylindole series tends to increase CB2 affinity, but often at the expense of CB1 binding.[1] JWH-098 is illegal in Russia,[2] Sweden,[3] and the UK,[4] although it is unclear whether it has any history of human use.
See also
References
- ^ Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson ALS, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR. Structure–activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorganic and Medicinal Chemistry. 2005; 13:89-112. PMID 15582455
- ^ "Постановление от 31 декабря 2009 г. № 1186 О внесении изменений в некоторые постановления Правительства Российской Федерации по вопросам, связанным с оборотом наркотических средств". Government.ru. http://www.government.ru/gov/results/8945/. Retrieved 2010-09-09.
- ^ Svensk författningssamling
- ^ The Misuse of Drugs Act 1971 (Amendment) Order 2009
|
|
Plant cannabinoids |
|
|
Cannabinoid metabolites |
|
|
Endogenous cannabinoids |
|
|
Synthetic cannabinoid
receptor agonists |
Classical cannabinoids
(Dibenzopyrans)
|
|
|
Nonclassical cannabinoids
|
|
|
Benzoylindoles
|
|
|
Naphthoylindoles
|
|
|
Naphthylmethylindoles
|
JWH-175 · JWH-184 · JWH-185 · JWH-192 · JWH-194 · JWH-195 · JWH-196 · JWH-197 · JWH-199
|
|
Phenylacetylindoles
|
|
|
Naphthoylpyrroles
|
|
|
Eicosanoids
|
|
|
Others
|
|
|
|
Allosteric modulators of
cannabinoid receptors |
|
|
Endocannabinoid
activity enhancers |
|
|
Cannabinoid receptor
antagonists and
inverse agonists |
|
|